Secondary analysis from the Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials examines improvements in lipid profiles for Lp(a), LDL-C and ApoB ...

CONSHOHOCKEN, Pa., April 09, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH ...

Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...

Patients in the Phase 3 MAESTRO-NAFLD-1 trial achieved a statistically significant mean reduction of 6.7 kPa in liver stiffness, the largest reported in compensated MASH cirrhosis populations. 51% of ...

Please provide your email address to receive an email when new articles are posted on . Experts recommend confirming MASH diagnosis by assessing steatosis via ultrasound or FibroScan. MRI-proton ...

Rezdiffra may affect the way other medicines work, and other medicines may affect how Rezdiffra works. Especially tell your healthcare provider if you take medicines that contain gemfibrozil to help ...

Credit: Madrigal Pharmaceuticals. Rezdiffra is supplied in 60mg-, 80mg-, and 100mg-strength tablets and is distributed through a limited specialty pharmacy network. Rezdiffra should be avoided in ...

On Wednesday, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported two-year results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra ...

Millions of Americans whose livers develop scar tissue due to a common disease now have the first approved drug, Rezdiffra, to treat the condition, the U.S. Food and Drug Administration announced ...

Madrigal Pharmaceuticals (MDGL) is back in focus after its first quarter 2026 earnings, where Rezdiffra delivered 127% year over year net sales growth to US$311.3 million, while the company still ...